Intranasal foralumab developer Tiziana Life Sciences announced the promotion of its Chief Medical Officer Matthew Davis to Chief Operating Officer. Davis, who joined Tiziana in July 2022, will continue to serve as Chief Medical Officer in addition to his role as COO. His previous experience includes roles at Endo, Lupin, and URL Pharma.
According to the company, Davis has been instrumental in advancing intranasal foralumab into Phase 2 development, with a Phase 2 trial of the human anti-CD3 mAb in patients with non-active secondary progressive multiple sclerosis scheduled for this year. Tiziana has also recently announced plans to develop intranasal foralumab for the treatment of hemorrhagic stroke, long COVID, diabetes, and Alzheimer’s disease.
Davis said, “I am honored to take on the role of Chief Operating Officer at Tiziana Life Sciences. I am excited to continue to work closely with the highly talented research and development team of Drs. Jules Jacobs and Vaseem Palejwala and build upon the strong foundation we have established. Together, as a company we will continue to drive the development and commercialization of transformative therapies that address unmet medical needs.”
Tiziana Executive Chairman Gabriele Cerrone commented, “Matthew’s promotion from Chief Medical Officer to Chief Operating Officer is a testament to his exceptional leadership skills and his significant contributions to Tiziana Life Sciences. His expertise in both clinical and operational aspects of the biotech industry will be instrumental in driving the company’s growth and bringing our promising therapeutic candidates to patients in need.”
Read the Tiziana Life Sciences press release.
